Last reviewed · How we verify
NCT06276374
Highest Efficacy of Dual Antiplatelet Therapy After Carotid Artery Stenting in High Bleeding Risk Patients
NA trial testing Intervention 1(DAPT): Drug: Aspirin 100mg + Clopidogrel 75mg. Intervention 2(SAPT): Drug: Asprin 100mg or Clopidogrel 75mg in Carotid Artery Diseases in 1,556 participants. Currently enrolling.
30 November 2029
Quick facts
| Lead sponsor | Woo-Keun Seo |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 1,556 |
| Start date | 15 July 2024 |
| Primary completion | 30 November 2029 |
| Estimated completion | 31 December 2030 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Intervention 1(DAPT): Drug: Aspirin 100mg + Clopidogrel 75mg. Intervention 2(SAPT): Drug: Asprin 100mg or Clopidogrel 75mg
Conditions studied
- Carotid Artery Diseases — all drugs for Carotid Artery Diseases →
Sponsor
Woo-Keun Seo — full company profile →
Who can join
19 and older, any sex, with Carotid Artery Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To compare the safety of dual antiplatelet therapy with aspirin and clopidogrel and single antiplatelet therapy administered from 30 days to 12 months following carotid artery stenting on clinically significant bleeding and its prevention effects on net clinical events including combined cardiovascular and cerebrovascular accidents and major bleeding events in patients with carotid artery disease who are at high bleeding risk.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Design and rationale of the clinical trial to obtain the highest efficacy of dual antiplatelet therapy after carotid artery stenting in high bleeding risk patients (CHET): A multicenter, randomized, open-label, superiority trial.
Kim HJ, Song TJ, Park MS, Baek JH, et al · · 2026 · PMID 41802529 · DOI 10.1016/j.ahj.2026.107418
Verify or expand the search:
- PubMed search for NCT06276374
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Carotid Artery Diseases
Currently open trials in the same condition.
- NCT07296965 — Oral Microbiome in Carotid Atherosclerosis · recruiting
- NCT06924593 — Study on the Trans-Carotid Artery Occlusion Shunt System · NA · recruiting
- NCT06653387 — A Single-arm, Pivotal Study to Evaluate Acute Device and Technical Success of the CGuard Prime Carotid Stent System When · NA · recruiting
- NCT06959628 — Study on the Trans-Carotid Artery Occlusion Shunt System Combined With Introducer Sets · NA · recruiting
- NCT06528717 — The Role of Maintaining External Carotid Artery Flow in Graft Interposition After Carotid Endarterectomy · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06276374 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Woo-Keun Seo
- Last refreshed: 22 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06276374.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing